CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5 enrolled
Drug / intervention
Aflibercept Ophthalmicdrug
Likely dose
Aflibercept Ophthalmic 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04970251
NCT04970251N/ACompleted
CompareCT.gov

Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular

Siriraj Hospital·interventional·Posted Jul 21, 2021·Updated Jul 21, 2021

In Brief

A clinical study evaluating Aflibercept Ophthalmic for Intraocular Pressure and 3 related conditions. Completed, enrolled 5 participants across 1 site.

Detailed Summary

Purpose: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG). Setting: Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Study design: Prospective interventional case series Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC if indicated. Best-collected visual acuity (BCVA), intraocular pressure (IOP), surgical complications, and number of anti-glaucoma medications were collected.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntraocular Pressure, Neovascular Glaucoma, Vascular Endothelial Growth Factor Overexpression, Glaucoma Secondary to Eye Inflammation
CountriesThailand
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 21, 2021
Enrollment StartNov 1, 2018
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 4.9 years ago

Interventions

Aflibercept Ophthalmicdrug

Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.